Tango Therapeutics (TNGX) Competitors $5.79 +0.14 (+2.55%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNGX vs. GMTX, APLS, ARWR, VCEL, TWST, KNSA, RXRX, DNLI, NAMS, and AGIOShould you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Vericel (VCEL), Twist Bioscience (TWST), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), NewAmsterdam Pharma (NAMS), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. Tango Therapeutics vs. Its Competitors Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Vericel Twist Bioscience Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Denali Therapeutics NewAmsterdam Pharma Agios Pharmaceuticals Tango Therapeutics (NASDAQ:TNGX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership. Do analysts prefer TNGX or GMTX? Tango Therapeutics currently has a consensus price target of $12.20, suggesting a potential upside of 110.56%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tango Therapeutics is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TNGX or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -322.67%. Gemini Therapeutics' return on equity of -38.78% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-322.67% -62.75% -39.94% Gemini Therapeutics N/A -38.78%-35.88% Which has more risk & volatility, TNGX or GMTX? Tango Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Does the media refer more to TNGX or GMTX? In the previous week, Tango Therapeutics had 10 more articles in the media than Gemini Therapeutics. MarketBeat recorded 10 mentions for Tango Therapeutics and 0 mentions for Gemini Therapeutics. Tango Therapeutics' average media sentiment score of 0.58 beat Gemini Therapeutics' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tango Therapeutics Positive Gemini Therapeutics Neutral Do insiders & institutionals have more ownership in TNGX or GMTX? 79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 7.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, TNGX or GMTX? Gemini Therapeutics has lower revenue, but higher earnings than Tango Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$42.07M14.93-$130.30M-$1.22-4.75Gemini TherapeuticsN/AN/A-$71.87M-$1.00-51.13 SummaryTango Therapeutics beats Gemini Therapeutics on 9 of the 15 factors compared between the two stocks. Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNGX vs. The Competition Export to ExcelMetricTango TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$625.95M$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-4.7321.2326.5720.02Price / Sales14.93280.33415.46120.95Price / CashN/A41.4736.1356.90Price / Book3.127.498.065.50Net Income-$130.30M-$55.05M$3.15B$248.50M7 Day Performance17.76%2.58%1.72%2.61%1 Month Performance78.83%5.22%3.92%5.42%1 Year Performance-30.53%5.04%35.02%20.76% Tango Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNGXTango Therapeutics2.3015 of 5 stars$5.79+2.5%$12.20+110.6%-30.2%$625.95M$42.07M-4.7390Analyst RevisionGMTXGemini TherapeuticsN/A$51.61+3.0%N/A+10.0%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5378 of 5 stars$17.62-0.4%$40.05+127.3%-49.1%$2.22B$781.37M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9385 of 5 stars$15.51+1.2%$43.71+181.8%-33.0%$2.12B$3.55M-11.08400Positive NewsVCELVericel2.8915 of 5 stars$41.80-0.5%$61.14+46.3%-8.0%$2.12B$237.22M1,393.80300Positive NewsTWSTTwist Bioscience4.4207 of 5 stars$35.33+2.0%$50.40+42.7%-20.4%$2.08B$312.97M-10.87990News CoveragePositive NewsKNSAKiniksa Pharmaceuticals International3.7215 of 5 stars$28.72+1.0%$38.80+35.1%+48.7%$2.08B$481.17M-114.88220Positive NewsRXRXRecursion Pharmaceuticals1.9044 of 5 stars$4.83-4.0%$7.00+44.9%-27.2%$2.04B$58.84M-2.73400Analyst ForecastDNLIDenali Therapeutics4.5662 of 5 stars$13.62-1.9%$33.71+147.5%-31.5%$2.02B$330.53M-5.10430NAMSNewAmsterdam Pharma3.0175 of 5 stars$18.21+1.4%$42.89+135.5%-6.6%$2.02B$45.56M-9.694Positive NewsAGIOAgios Pharmaceuticals4.0733 of 5 stars$33.34-3.1%$58.60+75.8%-15.9%$1.99B$36.50M2.97390 Related Companies and Tools Related Companies GMTX Competitors APLS Competitors ARWR Competitors VCEL Competitors TWST Competitors KNSA Competitors RXRX Competitors DNLI Competitors NAMS Competitors AGIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNGX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
